Trial · NCT07885462
Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills
NCT07885462, Phase 4, Not yet recruiting, Qilu Hospital of Shandong University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills. Trials, record NCT07885462. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885462
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills
- NCT number
- NCT07885462
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 496 participants, estimated
- Lead sponsor
- Qilu Hospital of Shandong University
- Conditions
- Coronary Microvascular Disease
- Interventions
- Compound Danshen Dripping Pills, Placebo
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in peak coronary flow reserve (CFRmax) of the left anterior descending artery | Baseline, 6 months, and 12 months | CFRmax is defined as the ratio of hyperemic to basal peak diastolic flow velocity (PDV) in the mid-to-distal left anterior descending artery, measured by transthoracic Doppler echocardiography (TTDE) during regadenoson-induced maximal hyperemia (regadenoson 0.4 mg/5 mL administered as a single intravenous bolus over approximately 10 seconds, followed by a saline flush). Measurements are performed at baseline, 6 months, and 12 months. Change from baseline at each time point is calculated as the value at that time point minus the baseline value. The primary analysis time point is 12 months. |
| Secondary | Change from baseline in mean coronary flow reserve (CFRmean) of the left anterior descending artery | Baseline, 6 months, and 12 months | CFRmean is defined as the ratio of hyperemic to basal mean diastolic flow velocity (MDV) in the mid-to-distal left anterior descending artery, measured by transthoracic Doppler echocardiography (TTDE) during regadenoson-induced maximal hyperemia (regadenoson 0.4 mg/5 mL administered as a single intravenous bolus over approximately 10 seconds, followed by a saline flush). Measurements are performed at baseline, 6 months, and 12 months. Change from baseline at each time point is calculated as the value at that time point minus the baseline value. |
| Secondary | Change from baseline in Seattle Angina Questionnaire (SAQ) score | Baseline, 3, 6, 9, and 12 months | The Seattle Angina Questionnaire (SAQ) is a disease-specific health status measure for coronary artery disease. Each of its five domains (Physical Limitation, Anginal Stability, Anginal Frequency, Treatment Satisfaction, and Disease Perception/Quality of Life) is scored from 0 to 100, with higher scores indicating better health status (fewer symptoms/limitations). Change from baseline is calculated as the score at each time point minus the baseline score. |
| Secondary | Change from baseline in CCS angina class | Baseline, 3, 6, 9, and 12 months | Angina severity is classified by the Canadian Cardiovascular Society (CCS) angina classification, ranging from Class I (angina only during strenuous exertion; least severe) to Class IV (angina at rest; most severe), where a higher class indicates a worse outcome. Improvement is defined as a reduction of ≥1 CCS class grade from baseline at each assessment time point. |
| Secondary | Incidence of major adverse cardiovascular events (MACE) within 12 months | From randomization/enrollment through 12 months | MACE is a composite endpoint defined as the occurrence of any of the following components during the 12-month follow-up period: (1) cardiovascular death; (2) non-fatal myocardial infarction; (3) hospitalization for angina pectoris; and (4) hospitalization for heart failure. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885462
GET https://conductscience.org/api/trials/v1/NCT07885462/registered